GURU.Markets stock price, segment price, and overall market index valuation
The company's share price MediWound Ltd.
MediWound is an Israeli biopharmaceutical company specializing in burn and wound treatment. Its stock price is dependent on sales of its innovative enzyme products and success in expanding their use.
Share prices of companies in the market segment - Treatment
MediWound is an Israeli biopharmaceutical company developing enzyme-based treatments for severe burns and wounds. We've categorized it as a Treatment company. The chart below shows how investors value companies in the niche but important field of regenerative medicine.
Broad Market Index - GURU.Markets
MediWound is an Israeli biopharmaceutical company developing enzyme-based treatments for severe burns and wounds. As a component of the GURU.Markets index, it represents the regenerative medicine sector. The chart below shows the US market. See how MediWound shares compare to the US market.
Change in the price of a company, segment, and market as a whole per day
MDWD - Daily change in the company's share price MediWound Ltd.
Shares of MediWound, a biopharmaceutical company, exhibit high volatility, as measured by change_co. This metric reflects sensitivity to news about clinical trials and the commercial success of its drugs. This metric is a key component of the formulas on System.GURU.Markets for analyzing risks in the biotech sector.
Daily change in the price of a set of shares in a market segment - Treatment
MediWound Ltd. is a biotech company. This chart highlights the sector's high volatility. Comparing it to MDWD, which focuses on burn and wound care, helps understand its unique risk profile in this niche.
Daily change in the price of a broad market stock, index - GURU.Markets
MediWound develops enzyme-based treatments for burns and wounds. It is a biotech company with a niche focus. Its shares respond to clinical data and commercial success, and their unique dynamics are part of the varied volatility of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization MediWound Ltd.
For MediWound Ltd., the year-over-year performance is a story of commercialization of its enzymatic burn and wound treatment products. Its 12-month market capitalization reflects its success in selling NexoBrid and securing contracts from US government agencies to supply this product for emergency response.
Annual dynamics of market capitalization of the market segment - Treatment
MediWound Ltd. is an Israeli biopharmaceutical company specializing in enzymatic treatments for burns and wounds. This chart illustrates how its unique niche technology, commercialization efforts, and reliance on government contracts influence its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mediwound is a biopharmaceutical company whose stock performance is driven by sales success of its burn treatments and research progress. The company's business is not dependent on economic cycles. The chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization MediWound Ltd.
The performance of MediWound, a biopharmaceutical company, depends on its product cycle. The monthly fluctuations on the chart reflect sales data for its burn and wound treatments, as well as news about clinical trials aimed at expanding their use.
Monthly dynamics of market capitalization of the market segment - Treatment
MediWound develops and markets enzyme-based treatments for burns and wounds. This is a highly specialized niche in biopharmaceuticals. The sector's dynamics reflect a general interest in innovative treatment methods. Against this backdrop, MediWound strives to establish its product as the standard of care for burns by demonstrating its effectiveness and cost-effectiveness.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
MediWound Ltd. is an Israeli biopharmaceutical company specializing in enzymatic treatments for severe burns and wounds. The company's future depends on the commercial success of its niche products. The broader market chart provides a backdrop for understanding the market success of its unique and vital products used in emergency medicine.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization MediWound Ltd.
MediWound Ltd. is an Israeli biopharmaceutical company developing enzyme-based treatments for burns and wounds. Its weekly stock price is driven by sales reports for its product, NexoBrid, and news of its approval and launch in new countries.
Weekly dynamics of market capitalization of the market segment - Treatment
MediWound develops enzyme-based treatments for burns and wounds. This is a highly specialized market. The company's shares respond to clinical trial results and regulatory approvals. The chart will show how much its performance is detached from general healthcare trends, following its own path.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
MediWound is a biotech company whose stock moves on news about clinical trials and regulatory decisions. This chart clearly demonstrates how much its performance is driven by scientific news rather than by general market trends, creating its own path.
Market capitalization of the company, segment and market as a whole
MDWD - Market capitalization of the company MediWound Ltd.
The market capitalization of MediWound, an Israeli biotech company, reflects its focus on enzymatic treatments for burns and wounds. This chart shows how investors assess the commercial potential of its innovative products. Price movements are driven by sales success and expanded indications.
MDWD - Share of the company's market capitalization MediWound Ltd. within the market segment - Treatment
MediWound is an Israeli biotech company that has developed a unique enzymatic drug for the non-surgical removal of dead tissue in severe burns. Its market share is still small, but its product is changing the standard of care. The chart shows the weight of this innovative company in niche medicine.
Market capitalization of the market segment - Treatment
Here's a chart showing the market capitalization of the biotech sector. MediWound is an Israeli company specializing in enzymatic treatment of burns and wounds. The size of this market reflects the enormous need for effective treatments. MediWound offers an innovative alternative to surgery, which is its core value.
Market capitalization of all companies included in a broad market index - GURU.Markets
MediWound develops enzyme-based treatments for severe burns and wounds. Its market capitalization is based on its unique wound-cleaning technology. The graph below shows the economic weight of the innovative tissue regeneration sector.
Book value capitalization of the company, segment and market as a whole
MDWD - Book value capitalization of the company MediWound Ltd.
MediWound's foundation is its intellectual property and manufacturing capabilities for creating biotherapeutic drugs for tissue regeneration, particularly for burn treatment. This chart tells the story of a biotech company commercializing its unique products and using the resulting capital to expand their applications.
MDWD - Share of the company's book capitalization MediWound Ltd. within the market segment - Treatment
MediWound develops treatments for burns and wounds. The chart shows its share of real assets. These include its biotech production facilities, where an enzymatic preparation for the gentle removal of dead tissue is produced from pineapple raw materials.
Market segment balance sheet capitalization - Treatment
MediWound, a biopharmaceutical company with its own manufacturing facility, is more capital-intensive than R&D startups. The chart below illustrates the scale of the entire pharmaceutical sector, providing context for assessing its integrated model.
Book value of all companies included in the broad market index - GURU.Markets
MediWound develops enzyme-based treatments for burns and wounds. The company's assets include its R&D and manufacturing facilities. Its stake in BCap_All provides the necessary resources for the development of innovative biotherapeutics that can significantly improve treatment outcomes.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - MediWound Ltd.
MediWound is a biopharmaceutical company. The premium to its assets reflects its unique product for enzymatic treatment of burns and wounds, as well as its potential for new medical applications.
Market to book capitalization ratio in a market segment - Treatment
MediWound develops and manufactures biotherapeutic solutions for burn and wound treatment. Its value lies in its unique enzyme formulations. The chart shows the premium the market pays for its innovative products and the potential to change treatment standards in its niche.
Market to book capitalization ratio for the market as a whole
MediWound develops and markets enzyme-based treatments for burns and wounds. It is a niche biopharmaceutical company with a commercialized product. This chart helps understand how the market values companies whose innovations are already generating revenue but whose growth potential may still be significant.
Debts of the company, segment and market as a whole
MDWD - Company debts MediWound Ltd.
MediWound, a biotech company developing enzymatic treatments for burns and wounds, is using the capital to commercialize and expand the use of its products. Its debt strategy is aimed at funding clinical trials for new indications and building a marketing infrastructure to increase sales.
Market segment debts - Treatment
MediWound develops and manufactures biopharmaceuticals for the treatment of burns and wounds. This niche market requires specialized expertise and investment in clinical research. This chart illustrates the company's financial strategy for bringing its unique products to market and expanding their medical applications.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio MediWound Ltd.
MediWound develops and markets enzyme-based treatments for burns and wounds. Biotech businesses require significant investment in clinical trials and marketing. This chart shows the company's debt-to-equity ratio, which is an indicator of financial risk and its reliance on external investors to achieve profitability.
Market segment debt to market segment book capitalization - Treatment
MediWound Ltd. is an Israeli biotech company developing enzyme-based treatments for burns and wounds. The chart shows debt trends in their sector. It allows one to assess how the company finances the commercialization of its unique products and how its financial strategy compares to other players in the wound care market.
Debt to book value of all companies in the market
MediWound Ltd. develops and commercializes drugs for the treatment of burns and wounds. Biopharmaceutical companies with approved products can generate revenue, but may also incur debt for marketing and further research. This chart allows us to evaluate MediWound's financial policy. How conservative is it compared to the overall debt burden in the economy, as shown in the chart?
P/E of the company, segment and market as a whole
P/E - MediWound Ltd.
MediWound is an Israeli biopharmaceutical company developing enzyme-based treatments for burns and wounds. This chart shows how the market assesses the commercial potential of its unique products. This assessment depends on the sales success of its current products and the results of clinical trials for new applications.
P/E of the market segment - Treatment
This chart shows the average valuation for biopharmaceutical companies, providing context for MediWound. It reflects overall investor sentiment toward the sector. Comparisons with this valuation help us understand whether MediWound's niche business, developing enzyme treatments for burns and wounds, is valued more or less optimistically by the market than its competitors.
P/E of the market as a whole
MediWound develops and markets enzyme-based treatments for burns and wounds. It's a niche biopharmaceutical company. This chart of overall healthcare sentiment helps us understand how investors value companies with a narrow focus. Do they value expertise in a single area or are they wary of being dependent on a small number of products?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company MediWound Ltd.
MediWound is a biopharmaceutical company developing enzyme-based treatments for severe burns and chronic wounds. This chart shows the expected value of its niche products. The valuation depends on the commercial success of its products, their expanded use, and partnerships to enter new markets.
%20P%2FE%20MediWound%20Ltd.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-MediWound-Ltd.&v=1772608903661 "Chart of the company's future (projected) P/E MediWound Ltd.")
Future (projected) P/E of the market segment - Treatment
MediWound is a biopharmaceutical company specializing in the development, production, and commercialization of products for the treatment of severe burns and chronic wounds. This chart reflects investor expectations for the company's profitability relative to the sector. It provides an insight into the market's perception of its innovative tissue regeneration solutions.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Treatment&v=1772608903674 "Future (projected) P/E graph of the market segment - Treatment")
Future (projected) P/E of the market as a whole
MediWound develops and markets innovative enzyme-based treatments for burns and chronic wounds. Despite the general market fluctuations illustrated by this chart, MediWound's business is driven by medical needs. Demand for their products depends on the number of patients with severe wounds and the acceptance of their technology by the medical community, not on the state of the economy.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772608903689 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit MediWound Ltd.
MediWound is an Israeli biotech company that has developed an innovative enzyme-based treatment for the non-surgical removal of necrotic tissue from burns and wounds. This chart shows the financial results of the company, whose product has the potential to change the standard of care in burn and wound care.
Profit of companies in the market segment - Treatment
MediWound develops and manufactures innovative enzyme-based treatments for burns and wounds. This chart shows the profitability of the biotech sector. For MDWD, this reflects the need for new, more effective wound treatments. Their products have the potential to significantly improve patient outcomes and reduce healthcare costs.
Overall market profit
MediWound is an Israeli biopharmaceutical company that has developed an innovative enzyme-based treatment for the non-surgical removal of dead tissue from burns and wounds. This is a niche product that has the potential to change the standard of care. The company's success depends on its commercialization. This gross margin graph does not reflect the prospects for unique medical products.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company MediWound Ltd.
MediWound is an Israeli biotech company that has developed NexoBrid, an innovative enzyme-based treatment for non-surgical eschar removal in severe burns. The revenue projections presented here are contingent on the successful commercialization of this product in the US and other countries, as well as the development of its other developments.
%20profit%20of%20the%20company%20MediWound%20Ltd.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-MediWound-Ltd.&v=1772608903912 "Graph of future (projected) profit of the company MediWound Ltd.")
Future (predicted) profit of companies in the market segment - Treatment
MediWound Ltd. develops enzyme-based treatments for severe burns and wounds. The revenue forecast for this niche pharmaceutical sector depends on the acceptance of its products in hospitals and emergency centers. This chart reflects analysts' expectations regarding the commercial potential of innovative wound treatments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Treatment&v=1772608903951 "Graph of future (predicted) profits of companies in a market segment - Treatment")
Future (predicted) profit of the market as a whole
MediWound develops and markets enzyme-based treatments for burns and wounds. The company's success depends on the adoption of its products in hospitals. The revenue projections presented here impact healthcare budgets, which affect hospitals' ability to purchase innovative, but more expensive, treatments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772608903982 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - MediWound Ltd.
MediWound is an Israeli biotech company developing enzymatic treatments for burns and wounds. This chart shows the market's estimated revenue from sales of its innovative product, NexoBrid. The estimate depends on successful commercialization in the US and other countries, as well as the expansion of its indications.
P/S market segment - Treatment
MediWound develops, manufactures, and commercializes innovative biotherapeutic solutions for the treatment of severe burns and chronic wounds. Its products accelerate healing. This chart shows the average revenue estimate for the biotech sector, helping to understand how the market values MediWound's unique products and market niche.
P/S of the market as a whole
MediWound is an Israeli biopharmaceutical company specializing in the treatment of severe burns and chronic wounds using enzyme-based therapies. The company's products offer an innovative alternative to surgical intervention. This chart provides a general market backdrop for assessing investor sentiment regarding revenue prospects in the niche biotech segment.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company MediWound Ltd.
MediWound develops and markets biotherapeutic products for the treatment of severe burns and chronic wounds. This chart shows how investors estimate the company's future sales. It reflects the need for innovative treatments that can accelerate healing and reduce scarring.
%20P%2FS%20MediWound%20Ltd.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-MediWound-Ltd.&v=1772608904030 "The graph of the company's future (projected) P/S MediWound Ltd.")
Future (projected) P/S of the market segment - Treatment
MediWound Ltd. develops and markets biotherapeutics for burn and wound treatment. Its enzyme-based products offer an innovative alternative to surgical debridement. This chart reflects how the market perceives its unique technology and its potential to transform wound care standards.
%20P%2FS%20market%20segment%20graph%20-%20Treatment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Treatment&v=1772608904099 "Future (projected) P/S market segment graph - Treatment")
Future (projected) P/S of the market as a whole
MediWound develops and markets biotherapeutic products for burn and wound treatment. Demand for their innovative products depends on their acceptance by the medical community. This graph, reflecting the state of the healthcare system, is important. Economic stability provides funding for hospitals and burn centers, allowing them to utilize cutting-edge treatments like MDWD products.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772608904130 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales MediWound Ltd.
MediWound is a biopharmaceutical company focused on the treatment of severe burns and wounds. Its flagship product, NexoBrid, enzymatically removes dead tissue without surgical intervention. This chart shows the sales revenue of this innovative product. Revenue growth is dependent on its adoption in burn centers worldwide.
Sales of companies in the market segment - Treatment
MediWound is an Israeli biopharmaceutical company specializing in the treatment of severe burns and chronic wounds. Their flagship product, NexoBrid, allows for the rapid removal of dead tissue without surgery. Their revenue comes from sales of this innovative product and government contracts.
Overall market sales
MediWound is a biopharmaceutical company that has developed an innovative enzyme-based product for the non-surgical removal of dead tissue in severe burns and chronic wounds. This eliminates the need for surgery and accelerates healing. This revenue chart includes the healthcare sector, where MDWD offers a unique and effective solution to a complex medical problem.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company MediWound Ltd.
MediWound is an Israeli biopharmaceutical company that produces pineapple enzyme-based treatments for severe burns and chronic wounds. This chart shows analysts' expectations for sales growth of its products to burn centers and wound care specialists worldwide.
%20sales%20of%20the%20company%20MediWound%20Ltd.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-MediWound-Ltd.&v=1772608904227 "Schedule of future (projected) sales of the company MediWound Ltd.")
Future (projected) sales of companies in the market segment - Treatment
MediWound develops and markets innovative enzyme-based treatments for severe burns and chronic wounds. This chart shows forecasts for the entire wound care market. It reflects the need for more effective and less invasive treatments that can accelerate healing and reduce healthcare costs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Treatment&v=1772608904269 "Schedule of future (projected) sales of companies in the market segment - Treatment")
Future (projected) sales of the market as a whole
MediWound Ltd., a biotech company specializing in burn and wound treatment, sees this chart as a reflection of the state of healthcare systems and emergency preparedness. The stable economic growth projected here provides funding for hospitals and the purchase of innovative drugs for the treatment of severe injuries.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772608904290 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality MediWound Ltd.
MediWound is a biopharmaceutical company specializing in burn and wound treatment products. Its business model is based on the commercialization of its innovative drugs. This chart shows how successfully the company converts sales revenue from its specialized therapeutics into net profit, covering research and marketing expenses.
Market segment marginality - Treatment
MediWound develops and markets biotherapeutic drugs for tissue regeneration and burn treatment. This indicator reflects the commercial success of its innovative products. This high result demonstrates the clinical efficacy of its products and their demand in specialized burn centers worldwide.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company MediWound Ltd.
MediWound is an Israeli biopharmaceutical company that has developed an innovative enzymatic drug for the non-surgical removal of dead tissue in severe burns. This graph shows the small team commercializing this unique product, which has the potential to significantly improve treatment outcomes for burn patients.
Share of the company's employees MediWound Ltd. within the market segment - Treatment
MediWound Ltd. develops, manufactures, and commercializes innovative enzyme-based treatments for burns and wounds. Replacing surgical wound debridement requires clinical evidence and a team of specialists to train physicians. This chart shows how the company is changing the standard of care by consolidating talent in this field.
Number of employees in the market segment - Treatment
MediWound develops, manufactures, and markets innovative enzyme-based treatments for severe burns and chronic wounds. The company's products remove dead tissue without surgery. This graphic shows the team of scientists and clinicians offering a revolutionary approach to wound treatment, accelerating healing and reducing risks.
Number of employees in the market as a whole
MediWound Ltd. is a biotechnology company developing enzyme-based treatments for burns and wounds. Economic stability, reflected in this chart, is essential for the implementation of their innovations. A strong labor market supports funding for hospitals and burn centers, allowing them to utilize the advanced and more effective treatments offered by MediWound.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company MediWound Ltd. (MDWD)
MediWound Ltd. is an Israeli biopharmaceutical company developing treatments for burns and wounds. This chart shows the valuation of their unique product. The company's valuation per employee may be high, as the company, with a relatively small staff, has brought to market an innovative product that fills an important medical niche.
%20of%20the%20company%20MediWound%20Ltd.%20(MDWD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-MediWound-Ltd.-MDWD&v=1772608904770 "Chart of market capitalization per employee (in thousands of dollars) of the company MediWound Ltd. (MDWD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Treatment
MediWound is a biopharmaceutical company developing enzyme-based treatments for burns and wounds. Its value is determined by the uniqueness of its products and clinical results. This chart shows how the market values its intellectual property and growth potential per employee compared to other biotech companies.
%20by%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Treatment&v=1772608904820 "Market capitalization per employee (in thousands of dollars) by market segment - Treatment")
Market capitalization per employee (in thousands of dollars) for the overall market
MediWound is an Israeli biopharmaceutical company developing enzyme-based treatments for burns and wounds. In this niche, this indicator reflects the value of its unique products. It shows how the market values its technology, which offers a new, less invasive method for wound cleansing, which generates high valuation.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772608904868 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company MediWound Ltd. (MDWD)
MediWound is an Israeli biotech company with NexoBrid, a product for treating severe burns. This chart shows how the company is commercializing its unique product. It's a niche product, but theirs allows patients to avoid surgery. Efficiency is the ability to convince burn centers to use their technology, which has a high profit margin.
%20Chart%20MediWound%20Ltd.%20(MDWD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-MediWound-Ltd.-MDWD&v=1772608904893 "Company Profit Per Employee (in thousands of dollars) Chart MediWound Ltd. (MDWD)")
Profit per employee (in thousands of dollars) in the market segment - Treatment
MediWound is a biotech company specializing in the treatment of severe burns and chronic wounds. Their product, NexoBrid, uses enzymes to non-surgically remove dead tissue. This graph represents an industry benchmark. In the niche pharmaceutical/biotech space, it reflects how effectively MediWound's team (R&D, sales) commercializes their unique product for specialized burn centers.
%20in%20the%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Treatment&v=1772608904924 "Chart of profit per employee (in thousands of dollars) in the market segment - Treatment")
Profit per employee (in thousands of dollars) for the market as a whole
MediWound is an Israeli biopharmaceutical company specializing in burn and wound treatment. Their flagship product (NexoBrid) is an enzymatic drug that selectively removes dead tissue (eschar) without surgery. It's a niche biotechnology. This graph shows how effectively their small team (R&D and sales) can market this unique and expensive drug in burn centers.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772608904941 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee MediWound Ltd. (MDWD)
MediWound develops and markets enzyme-based treatments for burns and wounds. This chart shows the commercialization of the biotech product. The increase in revenue per employee reflects increased sales of its innovative product, NexoBrid, which enables non-surgical removal of dead tissue and is a breakthrough in burn treatment.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-MediWound-Ltd.-MDWD&v=1772608905006 "Sales chart per company employee MediWound Ltd. (MDWD)")
Sales per employee in the market segment - Treatment
MediWound (MDWD) is an Israeli biotech company that produces enzyme-based treatments for severe burns and wounds (NexoBrid). This is a niche product at the intersection of biotech and surgery. This chart shows how efficient their model (R&D, manufacturing, sales) is in generating revenue per employee compared to the industry.
Sales per employee for the market as a whole
MediWound is an Israeli biotech company specializing in the treatment of severe burns and wounds. Their flagship product (NexoBrid) is an enzyme-based treatment that non-surgically removes dead tissue. This chart shows how their R&D and sales teams are monetizing this highly specialized product.
Short shares by company, segment and market as a whole
Shares shorted by company MediWound Ltd. (MDWD)
MediWound (MDWD) is an Israeli biotech company developing enzyme-based treatments for severe burns (NexoBrid) and chronic wounds. This chart measures bearish bets. The rise in shorts may reflect investor doubts about the commercial success of their niche products or difficulties in implementing them into standard burn treatment practices.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-MediWound-Ltd.-MDWD&v=1772608905212 "Short Shares Chart for the Company MediWound Ltd. (MDWD)")
Shares shorted by market segment - Treatment
MediWound (MDWD) is an Israeli company developing enzymatic treatments for severe burns (NexoBrid) and chronic wounds. This chart reflects the overall sentiment in the biotech sector. It shows how many investors doubt the commercial success of their niche drugs or anticipate regulatory challenges.
Shares shorted by the overall market
MediWound develops enzyme preparations for the treatment of severe burns and wounds. This is a critical, non-discretionary medical treatment. Demand for the company's products is driven by emergencies and patient injuries, not economic pressures. This makes MDWD's business highly insulated from the general market turmoil depicted by this chart.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator MediWound Ltd. (MDWD)
MediWound (MDWD) is an Israeli biotech company. Their key product, NexoBrid, is an enzymatic treatment for the non-surgical removal of dead tissue in severe burns. This chart measures hype. It shows "overheated" (above 70) on news of FDA approval or "oversold" (below 30) amid slow commercialization or delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-MediWound-Ltd.-MDWD&v=1772608905366 "RSI 14 indicator chart for the company's stock MediWound Ltd. (MDWD)")
RSI 14 Market Segment - Treatment
MediWound (MDWD) is an Israeli company that developed NexoBrid, an enzymatic (non-surgical) method for removing dead tissue from severe burns. This chart tracks the overall sentiment in the Medical Services/Biotech sector. It helps investors understand whether MDWD's performance reflects its unique niche in burn therapy or whether the entire sector is overheated or oversold.
RSI 14 for the overall market
MediWound (MDWD) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MDWD (MediWound Ltd.)
MediWound is an Israeli biopharmaceutical company that produces NexoBrid, an enzyme-based treatment for the non-surgical removal of dead tissue (eschar) in severe burns. This chart shows the average target price from analysts, reflecting their expectations for the product's adoption in burn centers in the US and Europe.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MDWD-MediWound-Ltd.&v=1772608905455 "A chart showing analyst consensus forecasts for the expected stock price. MDWD (MediWound Ltd.)")
The difference between the consensus estimate and the actual stock price MDWD (MediWound Ltd.)
MediWound is an Israeli biotech company specializing in enzymatic (non-surgical) wound treatment. Their flagship product (NexoBrid) is a gel that "dissolves" dead tissue in severe burns. This chart shows how analysts assess the slow commercial adoption of this niche hospital product.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MDWD-MediWound-Ltd.&v=1772608905473 "A chart showing the difference between the consensus forecast and the actual stock price. MDWD (MediWound Ltd.)")
Analyst consensus forecast for stock prices by market segment - Treatment
MediWound (MDWD) is an Israeli biotech company that developed NexoBrid, an enzymatic gel that non-surgically removes dead tissue from severe burns. This chart shows analysts' overall expectations for the treatment sector, reflecting whether experts believe this innovative technology will be adopted by burn centers.
Analysts' consensus forecast for the overall market share price
MediWound is an Israeli biopharmaceutical company that produces pineapple enzyme-based treatments (NexoBrid) for the non-surgical removal of dead tissue in severe burns. This chart shows the overall market sentiment. For MediWound, a company with a niche but important product, general optimism is important for funding, but their growth is more dependent on hospital procurement and government funding (BARDA).
AKIMA index of the company, segment and market as a whole
AKiMA Company Index MediWound Ltd.
MediWound is an Israeli biotech company specializing in burn and wound treatment. Their flagship product (NexoBrid) is an enzymatic gel that dissolves dead tissue in burns, avoiding complex surgery. This graph summarizes their commercialization progress, reflecting their ability to convince burn centers to adopt their innovative, yet niche, product.
AKIMA Market Segment Index - Treatment
MediWound is an Israeli biopharmaceutical company specializing in the treatment of severe burns and wounds. Their flagship product, NexoBrid, removes dead tissue without surgery. This graph shows the average index for the treatment sector. It allows one to assess how MediWound's innovative product compares to the industry average.
The AKIM Index for the overall market
MediWound is a biopharmaceutical company specializing in enzymatic treatments for severe burns and wounds (NexoBrid). This chart, reflecting the market average, is a backdrop. It helps assess how this niche story with a commercial product and government support compares to overall economic trends.
